Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines
Summary
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the successful closing of $270 million Series A financing. We are thrilled to have the backing of such an exceptional group of investors, whose support further enables the growth of our organization and the meaningful expansion of our platform and portfolio.Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. Earlier in her career, she worked at The Boston Consulting Group in their healthcare practice area advising large and small biopharma companies on a variety of strategic and operational issues. As a healthcare banker at Goldman Sachs, Barclays Capital, and Lehman Brothers, he has advised on approximately $100 billion in biopharma and life sciences financing and strategic transactions across both large and small companies. The company is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, and protein replacement.